Teva Pharmaceutical Industries Ltd (TEVA)

54.33
0.40 0.73
NYSE : Health Care
Prev Close 54.73
Open 54.50
Day Low/High 54.03 / 54.76
52 Wk Low/High 48.01 / 72.31
Volume 2.63M
Avg Volume 6.35M
Exchange NYSE
Shares Outstanding 914.00M
Market Cap 49.93B
EPS 1.80
P/E Ratio 30.02
Div & Yield 1.36 (2.50%)

Latest News

Teva Announces Pricing Of Additional CHF1.0 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Announces Pricing Of Additional CHF1.0 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands IV B.

Teva Announces Pricing Of Additional €4.0 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Announces Pricing Of Additional €4.0 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands II B.

Teva (TEVA) Stock Down After Pricing in Debt Offering

Teva (TEVA) Stock Down After Pricing in Debt Offering

Teva Pharmaceuticals (TEVA) stock is lower after successfully pricing in a debt offering for $15 billion worth of senior notes.

'Mad Money' Lightning Round: Take Allergan Over Teva

'Mad Money' Lightning Round: Take Allergan Over Teva

Cramer is a fan of Danaher and says to stick with CBRL Group.

Teva Announces Pricing Of $15 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Announces Pricing Of $15 Billion Of Senior Notes In Connection With Pending Acquisition Of Actavis Generics

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it successfully priced a debt offering by its special purpose finance subsidiary Teva Pharmaceutical Finance Netherlands III B.

Jim Cramer's 'Mad Money' Recap: Was This a Bad Market Day? I'll Take It!

Jim Cramer's 'Mad Money' Recap: Was This a Bad Market Day? I'll Take It!

Monday's headlines predicted a gloomy earnings season, Cramer says. What were they thinking?

Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC

Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC

Teva Pharmaceuticals (TEVA) stock rating was upgraded to 'buy' from 'hold' at HSBC on Monday.

Teva Makes Good Use of Rate Climate to Fund Allergan deal

Teva Makes Good Use of Rate Climate to Fund Allergan deal

The Israeli pharmaceutical company ought to achieve good terms as fixed-income investors flock to corporate bonds.

Analysts' Actions -- Chipotle, Nvidia, Qualcomm, Teva and More

Analysts' Actions -- Chipotle, Nvidia, Qualcomm, Teva and More

Here are Friday's top research calls, including downgrades for Chipotle, Nvidia, Qualcomm and Teva Pharmaceuticals.

Allergan Deal Should Give Teva Va-Va-Voom

Allergan Deal Should Give Teva Va-Va-Voom

The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.

Teva Pharmaceuticals (TEVA) Stock Gaining, Announces Bond Sale

Teva Pharmaceuticals (TEVA) Stock Gaining, Announces Bond Sale

Teva Pharmaceuticals (TEVA) will raise $20 billion in a bond sale next week after giving a sunny second quarter outlook yesterday.

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

6 Big Stocks to Add to Your Buy List -- Plus 1 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Portfolio Positions We are Watching in Today's Trading

A look at how we are evaluating today’s market action.

Teva Pharmaceutical Industries (TEVA) Showing Unusual Social Activity Today

Teva Pharmaceutical Industries (TEVA) Showing Unusual Social Activity Today

Trade-Ideas LLC identified Teva Pharmaceutical Industries (TEVA) as an unusual social activity candidate

Why Teva Pharmaceuticals (TEVA) Stock Is Surging Today

Why Teva Pharmaceuticals (TEVA) Stock Is Surging Today

Teva Pharmaceuticals (TEVA) stock is advancing after upping its outlook and noting that the Allergan (AGN) deal should close any day.

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Pricing Stress may Weigh on Generic Drugmakers Ahead of Q2 Earnings

Endo Pharmaceuticals is most under pressure, analysts say.

Trade-Ideas: Teva Pharmaceutical Industries (TEVA) Is Today's Post-Market Leader Stock

Trade-Ideas: Teva Pharmaceutical Industries (TEVA) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Teva Pharmaceutical Industries (TEVA) as a post-market leader candidate

Teva To Host Conference Call And Webcast To Provide Preliminary Outlook For 2016-2019

Teva To Host Conference Call And Webcast To Provide Preliminary Outlook For 2016-2019

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host a conference call and webcast for the investment community on Wednesday, July 13, 2016 at 8:00 a.

Cramer: 10 Stocks That Need to Start Doing Better

Cramer: 10 Stocks That Need to Start Doing Better

They need to do something that makes them stand out as stocks you want to own, not avoid.

Teva And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA

Teva And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and the Huntington Study Group (HSG) today announced the publication of data from the Phase III, placebo-controlled and randomized First-HD ( First Time Use of...

Morning Movers: TSLA, TEVA, GS, MSFT, DIS

Tesla shares sink on delivery miss while Goldman Sachs looks to curb spending within its asset-management division.

Where's That Dip I Was Expecting?

For the first time in a while, the market will be both short- and intermediate-term overbought.

Teva Inches Closer to Completion of Allergan Generics Deal

Teva Inches Closer to Completion of Allergan Generics Deal

Australia's Mayne will shell out $652 million for a basket of generics products from Teva as the latter works to complete its pending Allergan generics purchase.

Teva Pharmaceuticals (TEVA) Stock Climbs on Generic Products Sale

Teva Pharmaceuticals (TEVA) Stock Climbs on Generic Products Sale

Teva Pharmaceuticals (TEVA) stock is higher in pre-market trading on Tuesday after Mayne Pharma (MAYNF) agreed to purchase generic drugs from the company.

Teva Announces FDA Acceptance Of New Drug Applications For Fluticasone Propionate/Salmeterol And Fluticasone Propionate RespiClick® Inhalers

Teva Announces FDA Acceptance Of New Drug Applications For Fluticasone Propionate/Salmeterol And Fluticasone Propionate RespiClick® Inhalers

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today that the U.

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc.

KMX, FB, AAPL: Jim Cramer's Views

KMX, FB, AAPL: Jim Cramer's Views

Cramer shares his views on how Brexit is going from molehill to mountain and wonders if anyone cares about market opportunities. Carmax, Facebook and Apple are among the stocks discussed.

Teva Receives CHMP Positive Opinion For CINQAERO® (reslizumab)

Teva Receives CHMP Positive Opinion For CINQAERO® (reslizumab)

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing...